CA2591551A1 - Isolated layer pulse oximetry - Google Patents
Isolated layer pulse oximetry Download PDFInfo
- Publication number
- CA2591551A1 CA2591551A1 CA002591551A CA2591551A CA2591551A1 CA 2591551 A1 CA2591551 A1 CA 2591551A1 CA 002591551 A CA002591551 A CA 002591551A CA 2591551 A CA2591551 A CA 2591551A CA 2591551 A1 CA2591551 A1 CA 2591551A1
- Authority
- CA
- Canada
- Prior art keywords
- detector
- patient
- wavelength
- oxygen saturation
- emitter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
- A61B2562/0242—Special features of optical sensors or probes classified in A61B5/00 for varying or adjusting the optical path length in the tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
Abstract
An apparatus of and method for measuring arterial blood oxygen saturation at a particular tissue level of interest. Visible and near infrared radiation is emitted into a patient at the measurement site using two different wavelengths. Detection at two different detection sites permits rejection of oxygen saturation at undesired tissue levels.
Description
ISOLATED LAYER PULSE OXIMETRY
Background of the Invention 1. Field of the Invention - The present invention generally relates to instruments which operate on the principal of pulse oximetry and more particularly relates to instruments which non-invasively measure oxygen saturation of arterial blood in vivo.
Background of the Invention 1. Field of the Invention - The present invention generally relates to instruments which operate on the principal of pulse oximetry and more particularly relates to instruments which non-invasively measure oxygen saturation of arterial blood in vivo.
2. Description of the Prior Art - Light in the visible and near infrared region of the electromagnetic spectrum has been used for the in vivo measurement of oxygen saturation levels of a patient's blood. Lewis et al. in U.S. Patent No. 5,139,025 and Lewis et al. in International Publication (PCT) Number WO 92/21283 discuss spectrophotometric instruments whereby the oxygen saturation of blood, both venous and arterial combined, is estimated using at least three electromagnetic sensor areas. A disadvantage of such instruments is that the accuracy of the oxygen saturation calculation is limited due to such calculation's sensitivity to varying parameters of the tissue other than blood saturation, for example a change in concentration. Rall, et al, in German Patent No. DE 43 04 693 teaches the use of a plurality of light sensors with a single light detector as the best means for oximetry measurement in the particular shape of the device of the invention, primarily'intended for connection to a fetus.
New, Jr. et al. in U.S. Patent No. 4,700,708 calculates arterial oxygen saturation by isolating the change in detected light intensities during a cardiac cvcle in an attempt to minimize and even eliminate the light scattering and absorption effects of noin-arteri.al blood tissue of a patient. Though this technique, known as pulse oximetry-, is effective in eliminating many of the artifacts introduced by bone, skin, muscle, etc. a disadvantage exists in that the signal acquisition and computation circuits must be very robust since the useful part of the signal is the relatively small change in detected intensities, as opposed to the total detected intensity. Another disadvantage is that the calculated oxygen saturation value is influenced by pulsatile signal contributions from many differing tissue layers, including the skin or surface tissue layer. It is often desirable to know the arterial oxygen _saturation of a particular tissue layer or range of tissue layers as opposed to knowing only a general average arterial oxygen saturation value for all layers, because the oxygen saturation value of the multiple layers may diff er from one another. Some clinical conditions, such as stasis, may continue to provide a pulsatile signal in the absence of flow, particularly near the outer surface.
New, Jr. et al. in U.S. Patent No. 4,700,708 calculates arterial oxygen saturation by isolating the change in detected light intensities during a cardiac cvcle in an attempt to minimize and even eliminate the light scattering and absorption effects of noin-arteri.al blood tissue of a patient. Though this technique, known as pulse oximetry-, is effective in eliminating many of the artifacts introduced by bone, skin, muscle, etc. a disadvantage exists in that the signal acquisition and computation circuits must be very robust since the useful part of the signal is the relatively small change in detected intensities, as opposed to the total detected intensity. Another disadvantage is that the calculated oxygen saturation value is influenced by pulsatile signal contributions from many differing tissue layers, including the skin or surface tissue layer. It is often desirable to know the arterial oxygen _saturation of a particular tissue layer or range of tissue layers as opposed to knowing only a general average arterial oxygen saturation value for all layers, because the oxygen saturation value of the multiple layers may diff er from one another. Some clinical conditions, such as stasis, may continue to provide a pulsatile signal in the absence of flow, particularly near the outer surface.
U.S. Patent No. 5,188,108 issued to Secker, suggests the use of a plurality of emitters and/or receivers to provide multiple emitter/receiver combination. The emitter/receiver spacing for each combination is selected to provide equivalent optical path lengths between combinations using different wavelengths of emission.
Summary of the Invention The present invention overcomes the disadvantages found in the prior art by providing a pulse oximetry system for the determination of arterial blood oxygen saturation level at a particular depth of tissue which readily compensates for limitations induced in the prior art systems. Specifica'Lly, the present invention allows for pulsed oximetry measurement which isolates arterial saturation levels for particular ranges of tissue layers which rejects saturation levels of the tissue above or below the tissue of interest by utilizing multiple spaced detectors and/or emitters.
According to one embodiment of the invention, a sensor for use with a pulse oximeter monitor comprises a patient interface housing for coupling to a patient; at least three sensor areas for emitting electromagnetic radiation which penetrates tissue of the patient and detects that electromagnetic radiation scattered by the tissue, a spacing between a first pair of electromagnetic emitter and electromagnetic detector being different than that of a spacing between a second pair of electromagnetic emitter and electromagnetic detector; and means for calculating an arterial oxygen saturation level of the patient in response to the detected electromagnetic radiation.
According to two preferred embodiments, the sensor areas comprise Ã-irst and second separated and spaced apart emitter areas each capable of generating light of at least two distinct wavelengths, and a detector, the first emitter area and the detector corresponding to a first pair of emitter and detector, the second emitter area and the detector corresponding to the second pair of emitter and detector; or the sensor areas comprise first and second detector areas each capable of detecting light of at least two separate wavelength values, and an emitter area capable of generating said light having the at least two separated wavelength values.
Brief Description of the Drawings Other objects of the present invention and many of the attendant advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, in which like reference numerals designate like parts throughout the figures thereof and wherein:
FIG. lA is a schematic diagram showing the basic principles of the present invention using a single emitter and multiple detectors;
FIG. 18 shows an alternative approach using multiple emitters and a single detector;
FIG. 2 is aaloseup perspective view of a portion of the patient contact element;
FIG. 3 is a partially sectioned view showing the operation of the present invention in vivo;
FIG. 4 is an overall block diagram showing the major components of an operational system employing the present invention;
FIG. 5 is a timing diagram for the operation of the embodiment of Fig. 4;
FIG. 6 is a graph of absorptivity vs. wavelength for various different oxygen saturation levels within the range of operation of the present invention; and FIG. 7 is a graph comprising calculated oxygen saturation values using the principles of the invention for deep and shallow tissue measurements, and values obtained without using the principles of the invention.
Summary of the Invention The present invention overcomes the disadvantages found in the prior art by providing a pulse oximetry system for the determination of arterial blood oxygen saturation level at a particular depth of tissue which readily compensates for limitations induced in the prior art systems. Specifica'Lly, the present invention allows for pulsed oximetry measurement which isolates arterial saturation levels for particular ranges of tissue layers which rejects saturation levels of the tissue above or below the tissue of interest by utilizing multiple spaced detectors and/or emitters.
According to one embodiment of the invention, a sensor for use with a pulse oximeter monitor comprises a patient interface housing for coupling to a patient; at least three sensor areas for emitting electromagnetic radiation which penetrates tissue of the patient and detects that electromagnetic radiation scattered by the tissue, a spacing between a first pair of electromagnetic emitter and electromagnetic detector being different than that of a spacing between a second pair of electromagnetic emitter and electromagnetic detector; and means for calculating an arterial oxygen saturation level of the patient in response to the detected electromagnetic radiation.
According to two preferred embodiments, the sensor areas comprise Ã-irst and second separated and spaced apart emitter areas each capable of generating light of at least two distinct wavelengths, and a detector, the first emitter area and the detector corresponding to a first pair of emitter and detector, the second emitter area and the detector corresponding to the second pair of emitter and detector; or the sensor areas comprise first and second detector areas each capable of detecting light of at least two separate wavelength values, and an emitter area capable of generating said light having the at least two separated wavelength values.
Brief Description of the Drawings Other objects of the present invention and many of the attendant advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, in which like reference numerals designate like parts throughout the figures thereof and wherein:
FIG. lA is a schematic diagram showing the basic principles of the present invention using a single emitter and multiple detectors;
FIG. 18 shows an alternative approach using multiple emitters and a single detector;
FIG. 2 is aaloseup perspective view of a portion of the patient contact element;
FIG. 3 is a partially sectioned view showing the operation of the present invention in vivo;
FIG. 4 is an overall block diagram showing the major components of an operational system employing the present invention;
FIG. 5 is a timing diagram for the operation of the embodiment of Fig. 4;
FIG. 6 is a graph of absorptivity vs. wavelength for various different oxygen saturation levels within the range of operation of the present invention; and FIG. 7 is a graph comprising calculated oxygen saturation values using the principles of the invention for deep and shallow tissue measurements, and values obtained without using the principles of the invention.
Detailed Description of the Preferred Embodiments FIG. 1A is a schematic diagram showing the principles of operation of the present invention. In this example, it is assumed desirable to measure the percentage of oxygen saturation within the arterial blood of patient 10 at subdermal tissue level 12 having light absorption properties ub. Interposed between the non-invasive monitoring and measurement system (not shown) and subdermal tissue level 12, is skin or surface tissue level 14 having light absorption properties u8. It is deemed desirable to measure arterial oxygen saturation in the tissue layer 12 or the tissue layer 14 independently.
According to a first preferred embodiment, emitter 16 transmits electromagnetic radiation in the visible and near infrared region at two predetermined wavelengths (e.g. 660 nm and 905 nm). Emitter 16 is shown as a single entity in this example. However, different emitters may be used for the different predetermined wavelengths, if desired. If more than one emitter is used, it is most convenient that they be co-located to simulate a single point source. LED's are a preferred type of emitter. The signals from emitter 16 travel generally along path 18 to a first detector 20 and along path 22 to a second detector 24 as shown. The length of path 18 within layer 12 (with absorption ub) is shown as L1 and the length :f path 22 within layer 12 is shown as L2.
Detector 20 is spaced a distance of rl from emitter 16 and detector 24 is spaced at a distance of r2.
As can be seen in the drawing, both path 18 and path 22 traverse skin layer 14 twice. Furthermore, because paths 18 and 22 traverse skin layer 14 using approximately the same angle, the primary difference between paths 22 and 18 is the difference between length L2 and length L1 traversing subdermal layer 12, which is the tissue layer of interest. Therefore, it can be assumed that the difference in absorption between path L.
and path L1 is directly attributable to subdermal layer 12, the tissue layer of interest, corresponding to the different spacings r2 and rl.
The path length through skin layer 12 may be represented by 1 and the deeper path through the subderinal tissue by L1 and L2, depending on which detector is considered. Note that multiple emitters may transmit to a single detector as discussed below in relation to Fig. 1B. Following the formalism of Beer's Law, the signal detected at D, 20 is given by:
I1 = Ioexp ( -ual ) ' exp ( -ubLl ) = exp ( -ual ) (1) which describes the attenuation of the signal traveling twice through the skin layer 14 and once through the subdermal tissue 12 where:
I1 = the detected light intensity at D, Io = the emitted light intensity of emitter E
ua = the characteristic absorption of layer 14 ub = the characteristic absorption of layer 12 1 the path length through layer 14 L1 = the path length through layer 12 The absorption coefficients can be rewritten as the product of the concentration of an absorbing constituent, [c], and its extinction coefficient A. In this case, [c]
is the concentration of total hemoglobin in the tissue.
Allowing for different concentrations in the two layers, equation 1 becomes:
I1 = Ioexp(-2Pa[ca]1 - f~b[Cb]I'1) (2) To include the venous contribution, /3[c] expands as follows:
P[c] becomes pan[c]art + h'ven[C]ven (3) Next is added the feature of pulse oximetry. Consider that the arterial blood concentration in both upper and lower layers vary with time following the cardiac cycle, and that the two layers may additionally have different pulse amplitudes. Assume the background venous blood concentration does not vary with the cardiac cycle.
Taken at any convenient point in time (e.g. maxima or minima of the cardiac cycle), the logarithm of equation 2, considering equation 3, becomes:
ln(I1\tl) ) -s IO - ~(~a,artLCa(tl) ]art + Ya,venLCa~ven)1 ( Yb, art L Cb ( tl )Iart + Yb,ven [Cb ]ven )I'1 (4) Subtracting the signal observed at a second point in time, this expression simplifies:
ln(11(t1) ) ln(I1(t2) ) - -2(Ya,art~LCa]art)1 - (Yb,art~LCblart)LS (5) where o[c],="t =[c(tl) ],,, -[c(t2) ]art. Recalling that we assume the contribution of the skin layer has the same influence on both detectors, we can write a similar expression for the signals observed at detector D2:
ln(I2(tl) ) - ln(12(t2) ) - -2lYa,art~LCa]art)1 (Nb,art~LCb]art)I2 (6) Subtracting equation 6 from equation 5, we find:
[ln(I1(tl) ) - ln(I1(ts) ) I -[ln(Iz(t1) )- ln(Iz(ts) Ab,art&[Cb]ert(L2 L1) (7) Notice that the contribution of the skin laye= has been eliminated. Finally, the measurements are repeated at a second wavelength. Taking the ratio of equation 7 evaluated at two wavelengths gives:
R = ( [ln(I1(t1) )-ln(I1(t2) ) J-[ln(I2 (t1) )-ln(Iz(tz) ) J )u~
( [ln(I1(t1) )-Tn(I1(t2) ) ]-[ln(I2(t1) )-ln(Ia(tz) ) 7 )~a -/3b,art,?.1 ( L2 I'1 ) ?,1 /h'b,art,A2 ( L2 I'1 ) ?,2 (8) Equation 8 is equivalent to conventional pulse oximetry if the second detector is eliminated. In the conventional, non-scattering, model of oximetry, it is assumed that the average path lengths are equal at the two wavelengths -- and they would simply drop out of equation 8. The model is improved, however, if the ratio of the average path lengths, or in this case the ratio of the difference lengths, is kept as an empirically determined correction factor:
R - ~b,art,hl~pb,art,?~ ' ALa1IGL~ ( 9 ) where oL = L2 - L1 . In conventional pulse oximetry, the ratio of average path lengths is stable over a useful (but limited) saturation range. With the proper choice of wavelengths, this useful range can be engineered to cover specific meaningful clinical windows ( e. g. , 70-100%
saturation or 40-60% saturation).
The extinction coefficient can be rewritten in oxygen saturation terminology as:
j3 = S ')3o.y+ (1-S ) 'pred (10) Where S=[O2Hb]/([O2Hb]+[Hb]) and where Aõy refers to oxygenated hemoglobin ( O2Hb ) and A1ed refers to reduced hemoglobin ( Hb ) From this point on in the derivation, everything follows the conventional approach to pulse oximetry, applying equation 10 to 9, and solving for S( SpO,) in terms of the observation R:
Sp02- [ Predk2-R * t'red~l ] / [ R ( h'oxy?.1-Yred~ l ) -~oxy? 2+~red12 ] ( 1 1 ) In equation 11, the ratio of LL's has been absorbed into the appropriate P's as these will ultimately be determined empirically according to a preferred embodiment of the invention.
According to a first preferred embodiment, emitter 16 transmits electromagnetic radiation in the visible and near infrared region at two predetermined wavelengths (e.g. 660 nm and 905 nm). Emitter 16 is shown as a single entity in this example. However, different emitters may be used for the different predetermined wavelengths, if desired. If more than one emitter is used, it is most convenient that they be co-located to simulate a single point source. LED's are a preferred type of emitter. The signals from emitter 16 travel generally along path 18 to a first detector 20 and along path 22 to a second detector 24 as shown. The length of path 18 within layer 12 (with absorption ub) is shown as L1 and the length :f path 22 within layer 12 is shown as L2.
Detector 20 is spaced a distance of rl from emitter 16 and detector 24 is spaced at a distance of r2.
As can be seen in the drawing, both path 18 and path 22 traverse skin layer 14 twice. Furthermore, because paths 18 and 22 traverse skin layer 14 using approximately the same angle, the primary difference between paths 22 and 18 is the difference between length L2 and length L1 traversing subdermal layer 12, which is the tissue layer of interest. Therefore, it can be assumed that the difference in absorption between path L.
and path L1 is directly attributable to subdermal layer 12, the tissue layer of interest, corresponding to the different spacings r2 and rl.
The path length through skin layer 12 may be represented by 1 and the deeper path through the subderinal tissue by L1 and L2, depending on which detector is considered. Note that multiple emitters may transmit to a single detector as discussed below in relation to Fig. 1B. Following the formalism of Beer's Law, the signal detected at D, 20 is given by:
I1 = Ioexp ( -ual ) ' exp ( -ubLl ) = exp ( -ual ) (1) which describes the attenuation of the signal traveling twice through the skin layer 14 and once through the subdermal tissue 12 where:
I1 = the detected light intensity at D, Io = the emitted light intensity of emitter E
ua = the characteristic absorption of layer 14 ub = the characteristic absorption of layer 12 1 the path length through layer 14 L1 = the path length through layer 12 The absorption coefficients can be rewritten as the product of the concentration of an absorbing constituent, [c], and its extinction coefficient A. In this case, [c]
is the concentration of total hemoglobin in the tissue.
Allowing for different concentrations in the two layers, equation 1 becomes:
I1 = Ioexp(-2Pa[ca]1 - f~b[Cb]I'1) (2) To include the venous contribution, /3[c] expands as follows:
P[c] becomes pan[c]art + h'ven[C]ven (3) Next is added the feature of pulse oximetry. Consider that the arterial blood concentration in both upper and lower layers vary with time following the cardiac cycle, and that the two layers may additionally have different pulse amplitudes. Assume the background venous blood concentration does not vary with the cardiac cycle.
Taken at any convenient point in time (e.g. maxima or minima of the cardiac cycle), the logarithm of equation 2, considering equation 3, becomes:
ln(I1\tl) ) -s IO - ~(~a,artLCa(tl) ]art + Ya,venLCa~ven)1 ( Yb, art L Cb ( tl )Iart + Yb,ven [Cb ]ven )I'1 (4) Subtracting the signal observed at a second point in time, this expression simplifies:
ln(11(t1) ) ln(I1(t2) ) - -2(Ya,art~LCa]art)1 - (Yb,art~LCblart)LS (5) where o[c],="t =[c(tl) ],,, -[c(t2) ]art. Recalling that we assume the contribution of the skin layer has the same influence on both detectors, we can write a similar expression for the signals observed at detector D2:
ln(I2(tl) ) - ln(12(t2) ) - -2lYa,art~LCa]art)1 (Nb,art~LCb]art)I2 (6) Subtracting equation 6 from equation 5, we find:
[ln(I1(tl) ) - ln(I1(ts) ) I -[ln(Iz(t1) )- ln(Iz(ts) Ab,art&[Cb]ert(L2 L1) (7) Notice that the contribution of the skin laye= has been eliminated. Finally, the measurements are repeated at a second wavelength. Taking the ratio of equation 7 evaluated at two wavelengths gives:
R = ( [ln(I1(t1) )-ln(I1(t2) ) J-[ln(I2 (t1) )-ln(Iz(tz) ) J )u~
( [ln(I1(t1) )-Tn(I1(t2) ) ]-[ln(I2(t1) )-ln(Ia(tz) ) 7 )~a -/3b,art,?.1 ( L2 I'1 ) ?,1 /h'b,art,A2 ( L2 I'1 ) ?,2 (8) Equation 8 is equivalent to conventional pulse oximetry if the second detector is eliminated. In the conventional, non-scattering, model of oximetry, it is assumed that the average path lengths are equal at the two wavelengths -- and they would simply drop out of equation 8. The model is improved, however, if the ratio of the average path lengths, or in this case the ratio of the difference lengths, is kept as an empirically determined correction factor:
R - ~b,art,hl~pb,art,?~ ' ALa1IGL~ ( 9 ) where oL = L2 - L1 . In conventional pulse oximetry, the ratio of average path lengths is stable over a useful (but limited) saturation range. With the proper choice of wavelengths, this useful range can be engineered to cover specific meaningful clinical windows ( e. g. , 70-100%
saturation or 40-60% saturation).
The extinction coefficient can be rewritten in oxygen saturation terminology as:
j3 = S ')3o.y+ (1-S ) 'pred (10) Where S=[O2Hb]/([O2Hb]+[Hb]) and where Aõy refers to oxygenated hemoglobin ( O2Hb ) and A1ed refers to reduced hemoglobin ( Hb ) From this point on in the derivation, everything follows the conventional approach to pulse oximetry, applying equation 10 to 9, and solving for S( SpO,) in terms of the observation R:
Sp02- [ Predk2-R * t'red~l ] / [ R ( h'oxy?.1-Yred~ l ) -~oxy? 2+~red12 ] ( 1 1 ) In equation 11, the ratio of LL's has been absorbed into the appropriate P's as these will ultimately be determined empirically according to a preferred embodiment of the invention.
This result differs from the conventional single detector pulse oximetry algorithm in that the skin layer signals are excluded from the measurement, regardless if the skin pulses or is non-pulsatile (e.g., vasoconstriction or exsanguination). Within the limitations of the assumptions made, as long as the upper skin layer does not create a shunt, and the deeper layer continues to pulse, this algorithm gives a result related only to the arterial blood saturation of the deeper tissue.
The separation of the first emitter/detector pair 16,20 (i.e. rl) and the second emitter/detector pair 16,24 (i.e. r2) should be larger than several times the skin thickness (i.e. r1,r2 much greater than d) so that the four occurrences of 1 are all approximately equal, or at least have equivalent counterparts influencing the two detectors. The detector separation from the emitter should also be large enough to probe "deep" enough, the probed depth somewhat less than the separation. The two detectors should not be too far separated from one another, however, or else the assumption of equivalent skin thickness may be violated. If the detectors are too close to each other, GL becomes 0 and the measurement becomes unstable (see equation 9).
It is also possible to solve for the skin's saturation explicitly, excluding the contribution of deeper pulsating tissues. Instead of subtracting equation 6 from 5, multiply equation 5 by Lz and equation 6 by L1, then subtract to form:
L2=[ln(I1(tl) )-ln(I1(t2) -LI=[ln(I2(t1) )-ln(I2(t2) 2( LI - L2 C. l art (12) The quotient of equation 12, evaluated at the two wavelengths becomes:
(L2=ln[II(tl) /I1(t2) ] - L1=ln[I2(tl) /I2(t2) ~ )).1/
(L,=ln[I1(tl) /I1(t2) ] - L1=ln[I2(t1) /I2(t2) ~ )).2 =
[ (1GL ) ).1 / ( ZGL ) ).Z ] = ( Aa,art.).1 / Qa.art,),2 ) (13) Now, utilizing the concept of the path length multiplier, defined as L/r, M will refer to the subdermal tissue and m for the skin layer. If oL is much less than rl, one can approximate that the path length multipliers are the same for the two detectors. This leaves us with:
I''1k1 = L1,,,1/rl approximates L2.),1/r2; m,.1 = 1).1/d (14a) M,.2 = L1,),z /rl approximates L2,),2/rz 1 m;, = 1;~2/d (14b) Substituting these definitions into equation 13 simplifies the result into a more useful form:
R = (r2=1.n[I1(t1) /I1(t2) J - rl=ln[I2(t1) /I,(t2) ] )),1/
(r2=ln[I1(t1)/I1(t2)) - r1=ln[I2(t1)/I2(t2)1 ):12 ' ml l/m?2 = Fa,art,1.1 / F'a.art,).2 ( 15 ) As with the subdermal calculation, the ratio of m?,,/mf, can be absorbed into the empirically determined constants. And just as in the previous calculation, the path-length-multiplier ratio is adequately stable over limited, but useful, windows of saturation. The positioning of the two detectors takes on more importance here, and thus would need to be reproducible in a preferred sensor embodiment. Calculation of SP02 follows in the same manner as in equations 9 through 11.
FIG. 1B is a schematic diagram, similar to Fig. 1A, showing the present invention employing multiple emitters 16 and 17 and a single detector 24. Those of skill in the art will appreciate that the operation is similar to that described above.
FIG. 2 is a perspective view of the preferred mode of patient interface device 26 employing the present invention. Planar surface 28 is placed into contact with 25. the skin of the patient during monitoring and measurement. If desirable, this position may be maintained via adhesive or other mechanical means known in the art. Further, if desirable, surface 28 may have a curvature, and may be either flexible or rigid.
During the time that planar surface 28 is in position, emitter 16, detector 20, and detector 24 are in direct contact with the skin of the patient" (see also Fig. 1). The spacing of emitter 16, detector 20, and detector 24 are-as previously discussed.
Wiring, not shown in this view, electrically couples emitter 16, detector 20, and detector 24 to the circuitry which performs the monitoring functions.
FIG. 3 is a partially sectioned view showing patient interface device 26 in operational position. Cable 32 conducts the electrical signals to and from the monitoring circuitry as described below. All other elements are as previously described.
FIG. 4 is a block diagram showing the entire monitoring and measurement system employing the present invention. According to a first preferred embodiment, multiplexer 36 and two wavelength driver 34 alternately turn on the red and infrared LED's 16 at a desired chop frequency (e.g. 1,600 hz). These red and infrared signals are detected by detectors 20 and 24 and amplified by current-to-voltage amplifiers 38 and 40. The outputs of transconductance amplifiers 38 and 40 are demultiplexed by DMUX 42 so as to generate a first and second wavelength signal for each of detectors Di (20) and D. (24), which generated signals are sent through integrating amplfiers 49, 51, 53 and 55 to be placed on, respectively, lines 50, 52, 54 and 56. These f irst and second wavelength signals are digitized by Analog/Digital Converter 46. The digitized signals are traiismitted to CPU 48 for calculating arterial oxygen saturation. A
preferred archit-ectural implementation of the control electronics is disclosed in PCT/US94/03546 Alternate control electronics are known in the art and could be used, if desired.
As previously described, if deep tissue properties are desired, CPU 48 calculates R using equation 8 and SP02 using equation 11 with constants (3=Qd,,:, ~3~,~=,,,, and f3ox~,,~ being stored in CPU memory, having been previously determined empirically. If shallow tissue properties are desired, CPU 48 calculates R using equation 15 and SPOZ using equation 11.
According to a preferred embodiment, CPU 48 identifies and qualifies arterial pulses from the signals Dõ al; Dõ 1,2 ; D2, ?-l; Dz , ?'2 using any of the signal processing techniques described in U.S. Patent Nos.
4,869,254; 5,078,136; 4,911,167; 4,934,372; 4,802,486;
and 4,928,692=
The separation of the first emitter/detector pair 16,20 (i.e. rl) and the second emitter/detector pair 16,24 (i.e. r2) should be larger than several times the skin thickness (i.e. r1,r2 much greater than d) so that the four occurrences of 1 are all approximately equal, or at least have equivalent counterparts influencing the two detectors. The detector separation from the emitter should also be large enough to probe "deep" enough, the probed depth somewhat less than the separation. The two detectors should not be too far separated from one another, however, or else the assumption of equivalent skin thickness may be violated. If the detectors are too close to each other, GL becomes 0 and the measurement becomes unstable (see equation 9).
It is also possible to solve for the skin's saturation explicitly, excluding the contribution of deeper pulsating tissues. Instead of subtracting equation 6 from 5, multiply equation 5 by Lz and equation 6 by L1, then subtract to form:
L2=[ln(I1(tl) )-ln(I1(t2) -LI=[ln(I2(t1) )-ln(I2(t2) 2( LI - L2 C. l art (12) The quotient of equation 12, evaluated at the two wavelengths becomes:
(L2=ln[II(tl) /I1(t2) ] - L1=ln[I2(tl) /I2(t2) ~ )).1/
(L,=ln[I1(tl) /I1(t2) ] - L1=ln[I2(t1) /I2(t2) ~ )).2 =
[ (1GL ) ).1 / ( ZGL ) ).Z ] = ( Aa,art.).1 / Qa.art,),2 ) (13) Now, utilizing the concept of the path length multiplier, defined as L/r, M will refer to the subdermal tissue and m for the skin layer. If oL is much less than rl, one can approximate that the path length multipliers are the same for the two detectors. This leaves us with:
I''1k1 = L1,,,1/rl approximates L2.),1/r2; m,.1 = 1).1/d (14a) M,.2 = L1,),z /rl approximates L2,),2/rz 1 m;, = 1;~2/d (14b) Substituting these definitions into equation 13 simplifies the result into a more useful form:
R = (r2=1.n[I1(t1) /I1(t2) J - rl=ln[I2(t1) /I,(t2) ] )),1/
(r2=ln[I1(t1)/I1(t2)) - r1=ln[I2(t1)/I2(t2)1 ):12 ' ml l/m?2 = Fa,art,1.1 / F'a.art,).2 ( 15 ) As with the subdermal calculation, the ratio of m?,,/mf, can be absorbed into the empirically determined constants. And just as in the previous calculation, the path-length-multiplier ratio is adequately stable over limited, but useful, windows of saturation. The positioning of the two detectors takes on more importance here, and thus would need to be reproducible in a preferred sensor embodiment. Calculation of SP02 follows in the same manner as in equations 9 through 11.
FIG. 1B is a schematic diagram, similar to Fig. 1A, showing the present invention employing multiple emitters 16 and 17 and a single detector 24. Those of skill in the art will appreciate that the operation is similar to that described above.
FIG. 2 is a perspective view of the preferred mode of patient interface device 26 employing the present invention. Planar surface 28 is placed into contact with 25. the skin of the patient during monitoring and measurement. If desirable, this position may be maintained via adhesive or other mechanical means known in the art. Further, if desirable, surface 28 may have a curvature, and may be either flexible or rigid.
During the time that planar surface 28 is in position, emitter 16, detector 20, and detector 24 are in direct contact with the skin of the patient" (see also Fig. 1). The spacing of emitter 16, detector 20, and detector 24 are-as previously discussed.
Wiring, not shown in this view, electrically couples emitter 16, detector 20, and detector 24 to the circuitry which performs the monitoring functions.
FIG. 3 is a partially sectioned view showing patient interface device 26 in operational position. Cable 32 conducts the electrical signals to and from the monitoring circuitry as described below. All other elements are as previously described.
FIG. 4 is a block diagram showing the entire monitoring and measurement system employing the present invention. According to a first preferred embodiment, multiplexer 36 and two wavelength driver 34 alternately turn on the red and infrared LED's 16 at a desired chop frequency (e.g. 1,600 hz). These red and infrared signals are detected by detectors 20 and 24 and amplified by current-to-voltage amplifiers 38 and 40. The outputs of transconductance amplifiers 38 and 40 are demultiplexed by DMUX 42 so as to generate a first and second wavelength signal for each of detectors Di (20) and D. (24), which generated signals are sent through integrating amplfiers 49, 51, 53 and 55 to be placed on, respectively, lines 50, 52, 54 and 56. These f irst and second wavelength signals are digitized by Analog/Digital Converter 46. The digitized signals are traiismitted to CPU 48 for calculating arterial oxygen saturation. A
preferred archit-ectural implementation of the control electronics is disclosed in PCT/US94/03546 Alternate control electronics are known in the art and could be used, if desired.
As previously described, if deep tissue properties are desired, CPU 48 calculates R using equation 8 and SP02 using equation 11 with constants (3=Qd,,:, ~3~,~=,,,, and f3ox~,,~ being stored in CPU memory, having been previously determined empirically. If shallow tissue properties are desired, CPU 48 calculates R using equation 15 and SPOZ using equation 11.
According to a preferred embodiment, CPU 48 identifies and qualifies arterial pulses from the signals Dõ al; Dõ 1,2 ; D2, ?-l; Dz , ?'2 using any of the signal processing techniques described in U.S. Patent Nos.
4,869,254; 5,078,136; 4,911,167; 4,934,372; 4,802,486;
and 4,928,692=
In addition, though R is determined in equations (6), (15) using maximum and minimum intensities occurring during the cardiac cycle, other points in the cardiac cycle could be utilized as well, including adjacent digital points using derivative signal processing techniques described in PCT/US94/03546 cited above.
According to a preferred embodiment, one wavelength is chosen from the red portion of the electromagnetic spectrum (e.g. 660 nm) and the other wavelength is chosen from the near infrared portion of the electromagnetic spectrum (e.g. 900 nm). The precise wavelength values are a matter of design choice depending cn the applicati.on. For sensors for detecti.ng fetal arterial oxygen saturation, a preferred wavelength pair is 735 nm, 905 nm, as disclosed in U.S. Patent Number 5,421,329.
FIG. 5 is a timing diagram zor the apparatus of Fig.
4. The clock signal, containing pulses 58, 60, 62, and 64, is produced by Pattern Generator 44 (see also Fig.
4). The clock pulses are preferably produced at a rate of about 1600 hz. Each of the clock pulses triggers an output of emitter 16 as shown by pulses 66, 68, 70, and 72. The first wavelength is emitted twice corresponding to timing signals 74 and 76. Thereafter, the second wavelength is emitted twice corresponding to timing signals 78 and 80.
The signal from the first wavelength as received by detector 20 is gated to Analog/Digital converter 46 by DMUX 42 via line 50 during times 82 and 83. The signal produced by the first wavelength as received by detector 24 is gated over line 54 at times 81 and 86. Similarly, the signal from the second wavelength emission is gated over lines 52 and 54 from detectors 20 and 24 at times 84 and 85, and times 87 and 88, respectively. The received signals are converted to digital form and transferred to CPU 48 for calculation of the oxygen saturation level.
FIG. 6 is a graphical representation of the absorptivities of the various saturation levels of arterial blood as a function of wavelength of emitter 16.
The wavelengths preferred in the instant invention are about 660 nm and about 905 nm. However, those of skill in the art will readily appreciate that the present invention may be satisfactorily practiced using other wavelengths.
FIG. 7 is a graph illustrating data obtained from computer models of arterial oxygen saturation calculated using traditional techniques for a single detector, and using first and second detectors as described in Fig. 1.
As can be seen, the ratios of the Deep track very closely with the ratios from the conventional system.
According to a preferred embodiment, one wavelength is chosen from the red portion of the electromagnetic spectrum (e.g. 660 nm) and the other wavelength is chosen from the near infrared portion of the electromagnetic spectrum (e.g. 900 nm). The precise wavelength values are a matter of design choice depending cn the applicati.on. For sensors for detecti.ng fetal arterial oxygen saturation, a preferred wavelength pair is 735 nm, 905 nm, as disclosed in U.S. Patent Number 5,421,329.
FIG. 5 is a timing diagram zor the apparatus of Fig.
4. The clock signal, containing pulses 58, 60, 62, and 64, is produced by Pattern Generator 44 (see also Fig.
4). The clock pulses are preferably produced at a rate of about 1600 hz. Each of the clock pulses triggers an output of emitter 16 as shown by pulses 66, 68, 70, and 72. The first wavelength is emitted twice corresponding to timing signals 74 and 76. Thereafter, the second wavelength is emitted twice corresponding to timing signals 78 and 80.
The signal from the first wavelength as received by detector 20 is gated to Analog/Digital converter 46 by DMUX 42 via line 50 during times 82 and 83. The signal produced by the first wavelength as received by detector 24 is gated over line 54 at times 81 and 86. Similarly, the signal from the second wavelength emission is gated over lines 52 and 54 from detectors 20 and 24 at times 84 and 85, and times 87 and 88, respectively. The received signals are converted to digital form and transferred to CPU 48 for calculation of the oxygen saturation level.
FIG. 6 is a graphical representation of the absorptivities of the various saturation levels of arterial blood as a function of wavelength of emitter 16.
The wavelengths preferred in the instant invention are about 660 nm and about 905 nm. However, those of skill in the art will readily appreciate that the present invention may be satisfactorily practiced using other wavelengths.
FIG. 7 is a graph illustrating data obtained from computer models of arterial oxygen saturation calculated using traditional techniques for a single detector, and using first and second detectors as described in Fig. 1.
As can be seen, the ratios of the Deep track very closely with the ratios from the conventional system.
Though the invention has been primarily described by reference to an apparatus having a single emitter area 16 which emits light of at least two differing and known wavelengths, and first and second separated detector areas 20, 24, it will be appreciated that the three sensor areas could also be achieved by having a single detector area and first and second separated emitter areas, each of which emit light at first and second differing and known wavelengths, as illustrated in Fig.
1B. According to a preferred embodiment, the signals are transmitted by the emitters and detected by the detectors using standard time signal multiplex techniques, though other signal multiplex techniques could alternately be used if desired (e.g. frequency multiplex). In addition, increased resolution between differing tissue layers is achievable if increased number of sensor areas is utilized. For example, a half dozen or more detector areas could be utilized in combination with a single emitter area, or half dozen or more dual wavelength emitter areas could be utilized in combination with a single detector area. In addition, the sensor areas could be aligned in a linear array, either straight or curved, or could be disposed in a two-dimensional array.
Each different emitter/detector spacing pair could be used to calculate an oxygen saturation using different pulse oximetry signal processing methodologies as disclosed, and these multiple saturation values could be processed to image the tissue layers beneath the sensor areas or to reveal other desired information regarding these tissue layers.
Having thus described the preferred modes of the present invention, those of ordinary skill in the art will be readily able to think of yet other embodiments within the scope of the claims hereto attached and wherein:
1B. According to a preferred embodiment, the signals are transmitted by the emitters and detected by the detectors using standard time signal multiplex techniques, though other signal multiplex techniques could alternately be used if desired (e.g. frequency multiplex). In addition, increased resolution between differing tissue layers is achievable if increased number of sensor areas is utilized. For example, a half dozen or more detector areas could be utilized in combination with a single emitter area, or half dozen or more dual wavelength emitter areas could be utilized in combination with a single detector area. In addition, the sensor areas could be aligned in a linear array, either straight or curved, or could be disposed in a two-dimensional array.
Each different emitter/detector spacing pair could be used to calculate an oxygen saturation using different pulse oximetry signal processing methodologies as disclosed, and these multiple saturation values could be processed to image the tissue layers beneath the sensor areas or to reveal other desired information regarding these tissue layers.
Having thus described the preferred modes of the present invention, those of ordinary skill in the art will be readily able to think of yet other embodiments within the scope of the claims hereto attached and wherein:
Claims (8)
1. An apparatus comprising:
a. a patient interface for coupling to a patient;
b. an emitter of electromagnetic radiation coupled to said patient interface;
c. a first detector coupled to said patient interface at a first distance from said emitter;
d. a second detector coupled to said patient interface at a second distance from said emitter;
e. a synchronizer for synchronizing an oxygen saturation measurement to a predetermined portion of a cardiac cycle of said patient;
and f. means coupled to said first and said second detectors and said synchronizer for computing oxygen saturation level of arterial blood of said patient.
a. a patient interface for coupling to a patient;
b. an emitter of electromagnetic radiation coupled to said patient interface;
c. a first detector coupled to said patient interface at a first distance from said emitter;
d. a second detector coupled to said patient interface at a second distance from said emitter;
e. a synchronizer for synchronizing an oxygen saturation measurement to a predetermined portion of a cardiac cycle of said patient;
and f. means coupled to said first and said second detectors and said synchronizer for computing oxygen saturation level of arterial blood of said patient.
2. An apparatus according to claim 1 wherein said emitter emits a plurality of predetermined wavelengths of electromagnetic radiation.
3. An apparatus according to claim 2 wherein said emitter emits two predetermined wavelengths of electromagnetic radiation.
4. A method of measuring oxygen saturation level of arterial blood at a measurement site of a patient comprising:
a. determining time of arrival of arterial pulse wavefront at said measurement site of said patient;
b. emitting a first wavelength of electromagnetic radiation at said measurement site of said patient;
c. measuring amplitude of said first wavelength of electromagnetic radiation at a first detector located at a first distance from said emitting;
d. measuring amplitude of said first wavelength of electromagnetic radiation at a second detector located at a second distance from said emitting;
e. emitting a second wavelength of electromagnetic radiation at said measurement site of said patient;
f. measuring amplitude of said second wavelength of electromagnetic radiation at said first detector located at said first distance from said emitting;
g. measuring amplitude of said second wavelength of electromagnetic radiation at said second detector located at said second distance from said emitting;
h. computing the arterial oxygen saturation level using said amplitude measuring of said first wavelength at said first detector and said second detector and using said amplitude measuring of said second wavelength at said first detector and said second detector.
a. determining time of arrival of arterial pulse wavefront at said measurement site of said patient;
b. emitting a first wavelength of electromagnetic radiation at said measurement site of said patient;
c. measuring amplitude of said first wavelength of electromagnetic radiation at a first detector located at a first distance from said emitting;
d. measuring amplitude of said first wavelength of electromagnetic radiation at a second detector located at a second distance from said emitting;
e. emitting a second wavelength of electromagnetic radiation at said measurement site of said patient;
f. measuring amplitude of said second wavelength of electromagnetic radiation at said first detector located at said first distance from said emitting;
g. measuring amplitude of said second wavelength of electromagnetic radiation at said second detector located at said second distance from said emitting;
h. computing the arterial oxygen saturation level using said amplitude measuring of said first wavelength at said first detector and said second detector and using said amplitude measuring of said second wavelength at said first detector and said second detector.
5. A method according to claim 4 wherein said computing further comprises:
a. rejecting oxygen saturation level of venous blood of said patient.
a. rejecting oxygen saturation level of venous blood of said patient.
6. A method according to claim 4 wherein said computing further comprises:
a. rejecting oxygen saturation level of blood at other than a predetermined tissue level of interest.
a. rejecting oxygen saturation level of blood at other than a predetermined tissue level of interest.
7. A method according to claim 5 wherein said computing further comprises:
a. rejecting oxygen saturation level of arterial blood at other than a predetermined tissue level of interest.
a. rejecting oxygen saturation level of arterial blood at other than a predetermined tissue level of interest.
8. A method according to claim 7 wherein said first distance and said second distance are selected to optimize measurement at said predetermined tissue level of interest.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/403,642 US5524617A (en) | 1995-03-14 | 1995-03-14 | Isolated layer pulse oximetry |
CA002215163A CA2215163C (en) | 1995-03-14 | 1996-03-14 | Isolated layer pulse oximetry |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002215163A Division CA2215163C (en) | 1995-03-14 | 1996-03-14 | Isolated layer pulse oximetry |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2591551A1 true CA2591551A1 (en) | 1996-09-19 |
Family
ID=39672030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002591551A Abandoned CA2591551A1 (en) | 1995-03-14 | 1996-03-14 | Isolated layer pulse oximetry |
CA002215163A Expired - Fee Related CA2215163C (en) | 1995-03-14 | 1996-03-14 | Isolated layer pulse oximetry |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002215163A Expired - Fee Related CA2215163C (en) | 1995-03-14 | 1996-03-14 | Isolated layer pulse oximetry |
Country Status (6)
Country | Link |
---|---|
US (2) | US5524617A (en) |
EP (1) | EP0812148B1 (en) |
JP (1) | JP3751638B2 (en) |
CA (2) | CA2591551A1 (en) |
DE (1) | DE69632628T2 (en) |
WO (1) | WO1996028085A1 (en) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902235A (en) * | 1989-03-29 | 1999-05-11 | Somanetics Corporation | Optical cerebral oximeter |
US5575284A (en) * | 1994-04-01 | 1996-11-19 | University Of South Florida | Portable pulse oximeter |
US5524617A (en) * | 1995-03-14 | 1996-06-11 | Nellcor, Incorporated | Isolated layer pulse oximetry |
US5995856A (en) * | 1995-11-22 | 1999-11-30 | Nellcor, Incorporated | Non-contact optical monitoring of physiological parameters |
DE19640807A1 (en) * | 1996-10-02 | 1997-09-18 | Siemens Ag | Noninvasive optical detection of oxygen supply to e.g. brain or liver |
US6018673A (en) | 1996-10-10 | 2000-01-25 | Nellcor Puritan Bennett Incorporated | Motion compatible sensor for non-invasive optical blood analysis |
JP3365227B2 (en) * | 1996-10-25 | 2003-01-08 | 花王株式会社 | Method and apparatus for measuring optical properties of skin surface condition |
US5830137A (en) | 1996-11-18 | 1998-11-03 | University Of South Florida | Green light pulse oximeter |
US5935076A (en) * | 1997-02-10 | 1999-08-10 | University Of Alabama In Huntsville | Method and apparatus for accurately measuring the transmittance of blood within a retinal vessel |
US5776060A (en) * | 1997-02-20 | 1998-07-07 | University Of Alabama In Huntsville | Method and apparatus for measuring blood oxygen saturation within a retinal vessel with light having several selected wavelengths |
IL121079A0 (en) | 1997-06-15 | 1997-11-20 | Spo Medical Equipment Ltd | Physiological stress detector device and method |
CA2303803A1 (en) * | 1997-06-17 | 1998-12-23 | Respironics, Inc. | Fetal oximetry system and sensor |
EP0941694B1 (en) * | 1997-09-05 | 2007-08-22 | Seiko Epson Corporation | Method for configuring a reflected light sensor |
AU1608099A (en) * | 1997-11-26 | 1999-06-15 | Somanetics Corporation | Method and apparatus for monitoring fetal cerebral oxygenation during childbirth |
JP3794449B2 (en) * | 1998-04-07 | 2006-07-05 | 株式会社島津製作所 | Optical measuring device |
EP1083822A4 (en) | 1998-06-11 | 2005-10-12 | S P O Medical Equipment Ltd | Physiological stress detector device and method |
AU4530399A (en) * | 1998-06-26 | 2000-01-17 | Triphase Medical Ltd. | A device for evaluating blood system properties |
US6061584A (en) * | 1998-10-28 | 2000-05-09 | Lovejoy; David A. | Pulse oximetry sensor |
JP4490587B2 (en) * | 1998-11-18 | 2010-06-30 | エルエーアー メディツィンテクニック ゲーエムベーハー | Device for noninvasive detection of oxygen metabolism in tissues |
US6353226B1 (en) | 1998-11-23 | 2002-03-05 | Abbott Laboratories | Non-invasive sensor capable of determining optical parameters in a sample having multiple layers |
US6615061B1 (en) | 1998-11-23 | 2003-09-02 | Abbott Laboratories | Optical sensor having a selectable sampling distance for determination of analytes |
US7047054B2 (en) * | 1999-03-12 | 2006-05-16 | Cas Medical Systems, Inc. | Laser diode optical transducer assembly for non-invasive spectrophotometric blood oxygenation monitoring |
US6675031B1 (en) | 1999-04-14 | 2004-01-06 | Mallinckrodt Inc. | Method and circuit for indicating quality and accuracy of physiological measurements |
US8224412B2 (en) | 2000-04-17 | 2012-07-17 | Nellcor Puritan Bennett Llc | Pulse oximeter sensor with piece-wise function |
ES2392818T3 (en) | 2000-04-17 | 2012-12-14 | Nellcor Puritan Bennett Llc | Pulse oximeter sensor with section function |
CA2416546C (en) * | 2000-07-21 | 2007-12-18 | Universitat Zurich | Probe and apparatus for measuring cerebral hemodynamics and oxygenation |
US6529752B2 (en) * | 2001-01-17 | 2003-03-04 | David T. Krausman | Sleep disorder breathing event counter |
US6748254B2 (en) | 2001-10-12 | 2004-06-08 | Nellcor Puritan Bennett Incorporated | Stacked adhesive optical sensor |
US6839580B2 (en) * | 2001-12-06 | 2005-01-04 | Ric Investments, Inc. | Adaptive calibration for pulse oximetry |
EP1485012B1 (en) * | 2002-02-27 | 2015-01-28 | Covidien LP | Method and apparatus for determining cerebral oxygen saturation |
US7003337B2 (en) * | 2002-04-26 | 2006-02-21 | Vivascan Corporation | Non-invasive substance concentration measurement using and optical bridge |
US8175666B2 (en) * | 2002-04-26 | 2012-05-08 | Grove Instruments, Inc. | Three diode optical bridge system |
AU2003254135B2 (en) | 2002-07-26 | 2006-11-16 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
US7190986B1 (en) | 2002-10-18 | 2007-03-13 | Nellcor Puritan Bennett Inc. | Non-adhesive oximeter sensor for sensitive skin |
DE10333075B4 (en) * | 2003-07-21 | 2011-06-16 | Siemens Ag | Method and device for training adjustment in sports, especially in running |
US20050049467A1 (en) * | 2003-08-28 | 2005-03-03 | Georgios Stamatas | Method for assessing pigmented skin |
WO2005099564A1 (en) * | 2003-11-14 | 2005-10-27 | Tsinghua University | An apparatus of and method for measuring the parameter of the blood oxygen metabolism in human tissue |
US7435214B2 (en) * | 2004-01-29 | 2008-10-14 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
US7194293B2 (en) | 2004-03-08 | 2007-03-20 | Nellcor Puritan Bennett Incorporated | Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics |
JP4515148B2 (en) * | 2004-05-17 | 2010-07-28 | セイコーインスツル株式会社 | Biological information measuring apparatus and biological information measuring method |
US20060253010A1 (en) * | 2004-09-28 | 2006-11-09 | Donald Brady | Monitoring device, method and system |
US20060079794A1 (en) * | 2004-09-28 | 2006-04-13 | Impact Sports Technologies, Inc. | Monitoring device, method and system |
US7887492B1 (en) | 2004-09-28 | 2011-02-15 | Impact Sports Technologies, Inc. | Monitoring device, method and system |
US8190223B2 (en) | 2005-03-01 | 2012-05-29 | Masimo Laboratories, Inc. | Noninvasive multi-parameter patient monitor |
US8055321B2 (en) | 2005-03-14 | 2011-11-08 | Peter Bernreuter | Tissue oximetry apparatus and method |
US7865223B1 (en) * | 2005-03-14 | 2011-01-04 | Peter Bernreuter | In vivo blood spectrometry |
EP1885235B1 (en) | 2005-05-12 | 2013-12-18 | Cas Medical Systems, Inc. | Improved method for spectrophotometric blood oxygenation monitoring |
US7590439B2 (en) | 2005-08-08 | 2009-09-15 | Nellcor Puritan Bennett Llc | Bi-stable medical sensor and technique for using the same |
US7657294B2 (en) | 2005-08-08 | 2010-02-02 | Nellcor Puritan Bennett Llc | Compliant diaphragm medical sensor and technique for using the same |
US7657295B2 (en) | 2005-08-08 | 2010-02-02 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7657293B2 (en) | 2005-09-08 | 2010-02-02 | Vioptix Inc. | Method for monitoring viability of tissue flaps |
US20070060808A1 (en) | 2005-09-12 | 2007-03-15 | Carine Hoarau | Medical sensor for reducing motion artifacts and technique for using the same |
US7899510B2 (en) | 2005-09-29 | 2011-03-01 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US8092379B2 (en) | 2005-09-29 | 2012-01-10 | Nellcor Puritan Bennett Llc | Method and system for determining when to reposition a physiological sensor |
US7904130B2 (en) | 2005-09-29 | 2011-03-08 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7869850B2 (en) | 2005-09-29 | 2011-01-11 | Nellcor Puritan Bennett Llc | Medical sensor for reducing motion artifacts and technique for using the same |
US7881762B2 (en) | 2005-09-30 | 2011-02-01 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
US7555327B2 (en) | 2005-09-30 | 2009-06-30 | Nellcor Puritan Bennett Llc | Folding medical sensor and technique for using the same |
US7483731B2 (en) | 2005-09-30 | 2009-01-27 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7486979B2 (en) | 2005-09-30 | 2009-02-03 | Nellcor Puritan Bennett Llc | Optically aligned pulse oximetry sensor and technique for using the same |
US8233954B2 (en) | 2005-09-30 | 2012-07-31 | Nellcor Puritan Bennett Llc | Mucosal sensor for the assessment of tissue and blood constituents and technique for using the same |
US8062221B2 (en) | 2005-09-30 | 2011-11-22 | Nellcor Puritan Bennett Llc | Sensor for tissue gas detection and technique for using the same |
US8965472B2 (en) * | 2005-10-21 | 2015-02-24 | Cas Medical Systems, Inc. | Method and apparatus for spectrophotometric based oximetry |
US8073518B2 (en) | 2006-05-02 | 2011-12-06 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
US20130035569A1 (en) * | 2006-05-03 | 2013-02-07 | Nellcor Puritan Bennett Llc | Method and apparatus for hemometry |
JP5062698B2 (en) * | 2006-05-31 | 2012-10-31 | 国立大学法人静岡大学 | Optical measurement apparatus, optical measurement method, and storage medium storing optical measurement program |
US8145288B2 (en) | 2006-08-22 | 2012-03-27 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8219170B2 (en) | 2006-09-20 | 2012-07-10 | Nellcor Puritan Bennett Llc | System and method for practicing spectrophotometry using light emitting nanostructure devices |
US8175671B2 (en) | 2006-09-22 | 2012-05-08 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8396527B2 (en) | 2006-09-22 | 2013-03-12 | Covidien Lp | Medical sensor for reducing signal artifacts and technique for using the same |
US8190224B2 (en) | 2006-09-22 | 2012-05-29 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US7869849B2 (en) | 2006-09-26 | 2011-01-11 | Nellcor Puritan Bennett Llc | Opaque, electrically nonconductive region on a medical sensor |
US8123695B2 (en) * | 2006-09-27 | 2012-02-28 | Nellcor Puritan Bennett Llc | Method and apparatus for detection of venous pulsation |
US7574245B2 (en) | 2006-09-27 | 2009-08-11 | Nellcor Puritan Bennett Llc | Flexible medical sensor enclosure |
US7890153B2 (en) | 2006-09-28 | 2011-02-15 | Nellcor Puritan Bennett Llc | System and method for mitigating interference in pulse oximetry |
US7796403B2 (en) | 2006-09-28 | 2010-09-14 | Nellcor Puritan Bennett Llc | Means for mechanical registration and mechanical-electrical coupling of a faraday shield to a photodetector and an electrical circuit |
US8068891B2 (en) | 2006-09-29 | 2011-11-29 | Nellcor Puritan Bennett Llc | Symmetric LED array for pulse oximetry |
US7684842B2 (en) | 2006-09-29 | 2010-03-23 | Nellcor Puritan Bennett Llc | System and method for preventing sensor misuse |
US8175667B2 (en) | 2006-09-29 | 2012-05-08 | Nellcor Puritan Bennett Llc | Symmetric LED array for pulse oximetry |
US7476131B2 (en) | 2006-09-29 | 2009-01-13 | Nellcor Puritan Bennett Llc | Device for reducing crosstalk |
US7680522B2 (en) | 2006-09-29 | 2010-03-16 | Nellcor Puritan Bennett Llc | Method and apparatus for detecting misapplied sensors |
US20080297764A1 (en) * | 2006-11-13 | 2008-12-04 | Weinmann Gerate Fur Medizin Gmbh + Co. Kg | Sensor for determining body parameters |
US20080208019A1 (en) * | 2007-02-22 | 2008-08-28 | Jerusalem College Of Technology | Modified Pulse Oximetry Technique For Measurement Of Oxygen Saturation In Arterial And Venous Blood |
US8109882B2 (en) * | 2007-03-09 | 2012-02-07 | Nellcor Puritan Bennett Llc | System and method for venous pulsation detection using near infrared wavelengths |
US8265724B2 (en) | 2007-03-09 | 2012-09-11 | Nellcor Puritan Bennett Llc | Cancellation of light shunting |
US8221326B2 (en) * | 2007-03-09 | 2012-07-17 | Nellcor Puritan Bennett Llc | Detection of oximetry sensor sites based on waveform characteristics |
US7894869B2 (en) | 2007-03-09 | 2011-02-22 | Nellcor Puritan Bennett Llc | Multiple configuration medical sensor and technique for using the same |
US8229530B2 (en) * | 2007-03-09 | 2012-07-24 | Nellcor Puritan Bennett Llc | System and method for detection of venous pulsation |
US8280469B2 (en) | 2007-03-09 | 2012-10-02 | Nellcor Puritan Bennett Llc | Method for detection of aberrant tissue spectra |
WO2008118993A1 (en) | 2007-03-27 | 2008-10-02 | Masimo Laboratories, Inc. | Multiple wavelength optical sensor |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US9622694B2 (en) | 2007-06-20 | 2017-04-18 | Vioptix, Inc. | Measuring cerebral oxygen saturation |
US8346328B2 (en) | 2007-12-21 | 2013-01-01 | Covidien Lp | Medical sensor and technique for using the same |
US8352004B2 (en) | 2007-12-21 | 2013-01-08 | Covidien Lp | Medical sensor and technique for using the same |
US8380272B2 (en) * | 2007-12-21 | 2013-02-19 | Covidien Lp | Physiological sensor |
US8366613B2 (en) | 2007-12-26 | 2013-02-05 | Covidien Lp | LED drive circuit for pulse oximetry and method for using same |
US8577434B2 (en) | 2007-12-27 | 2013-11-05 | Covidien Lp | Coaxial LED light sources |
US8452364B2 (en) | 2007-12-28 | 2013-05-28 | Covidien LLP | System and method for attaching a sensor to a patient's skin |
US8442608B2 (en) | 2007-12-28 | 2013-05-14 | Covidien Lp | System and method for estimating physiological parameters by deconvolving artifacts |
US8897850B2 (en) | 2007-12-31 | 2014-11-25 | Covidien Lp | Sensor with integrated living hinge and spring |
US8092993B2 (en) | 2007-12-31 | 2012-01-10 | Nellcor Puritan Bennett Llc | Hydrogel thin film for use as a biosensor |
US8070508B2 (en) | 2007-12-31 | 2011-12-06 | Nellcor Puritan Bennett Llc | Method and apparatus for aligning and securing a cable strain relief |
US8199007B2 (en) | 2007-12-31 | 2012-06-12 | Nellcor Puritan Bennett Llc | Flex circuit snap track for a biometric sensor |
US8437822B2 (en) | 2008-03-28 | 2013-05-07 | Covidien Lp | System and method for estimating blood analyte concentration |
US8112375B2 (en) | 2008-03-31 | 2012-02-07 | Nellcor Puritan Bennett Llc | Wavelength selection and outlier detection in reduced rank linear models |
US7887345B2 (en) | 2008-06-30 | 2011-02-15 | Nellcor Puritan Bennett Llc | Single use connector for pulse oximetry sensors |
US8071935B2 (en) | 2008-06-30 | 2011-12-06 | Nellcor Puritan Bennett Llc | Optical detector with an overmolded faraday shield |
US7880884B2 (en) | 2008-06-30 | 2011-02-01 | Nellcor Puritan Bennett Llc | System and method for coating and shielding electronic sensor components |
US8577431B2 (en) | 2008-07-03 | 2013-11-05 | Cercacor Laboratories, Inc. | Noise shielding for a noninvasive device |
US20100022861A1 (en) * | 2008-07-28 | 2010-01-28 | Medtronic, Inc. | Implantable optical hemodynamic sensor including an extension member |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
US8364220B2 (en) | 2008-09-25 | 2013-01-29 | Covidien Lp | Medical sensor and technique for using the same |
US8417309B2 (en) | 2008-09-30 | 2013-04-09 | Covidien Lp | Medical sensor |
US8914088B2 (en) | 2008-09-30 | 2014-12-16 | Covidien Lp | Medical sensor and technique for using the same |
US8423112B2 (en) | 2008-09-30 | 2013-04-16 | Covidien Lp | Medical sensor and technique for using the same |
WO2010056973A1 (en) | 2008-11-14 | 2010-05-20 | Nonin Medical, Inc. | Optical sensor path selection |
US8938279B1 (en) * | 2009-01-26 | 2015-01-20 | VioOptix, Inc. | Multidepth tissue oximeter |
US8452366B2 (en) | 2009-03-16 | 2013-05-28 | Covidien Lp | Medical monitoring device with flexible circuitry |
US8221319B2 (en) | 2009-03-25 | 2012-07-17 | Nellcor Puritan Bennett Llc | Medical device for assessing intravascular blood volume and technique for using the same |
US8509869B2 (en) | 2009-05-15 | 2013-08-13 | Covidien Lp | Method and apparatus for detecting and analyzing variations in a physiologic parameter |
US8634891B2 (en) | 2009-05-20 | 2014-01-21 | Covidien Lp | Method and system for self regulation of sensor component contact pressure |
US20100331640A1 (en) * | 2009-06-26 | 2010-12-30 | Nellcor Puritan Bennett Llc | Use of photodetector array to improve efficiency and accuracy of an optical medical sensor |
US8311601B2 (en) | 2009-06-30 | 2012-11-13 | Nellcor Puritan Bennett Llc | Reflectance and/or transmissive pulse oximeter |
US9010634B2 (en) | 2009-06-30 | 2015-04-21 | Covidien Lp | System and method for linking patient data to a patient and providing sensor quality assurance |
US8505821B2 (en) | 2009-06-30 | 2013-08-13 | Covidien Lp | System and method for providing sensor quality assurance |
US8391941B2 (en) | 2009-07-17 | 2013-03-05 | Covidien Lp | System and method for memory switching for multiple configuration medical sensor |
US8417310B2 (en) | 2009-08-10 | 2013-04-09 | Covidien Lp | Digital switching in multi-site sensor |
US8428675B2 (en) | 2009-08-19 | 2013-04-23 | Covidien Lp | Nanofiber adhesives used in medical devices |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
DE112010004682T5 (en) | 2009-12-04 | 2013-03-28 | Masimo Corporation | Calibration for multi-level physiological monitors |
GB201005919D0 (en) * | 2010-04-09 | 2010-05-26 | Univ St Andrews | Optical backscattering diagnostics |
US7884933B1 (en) | 2010-05-05 | 2011-02-08 | Revolutionary Business Concepts, Inc. | Apparatus and method for determining analyte concentrations |
US8649838B2 (en) | 2010-09-22 | 2014-02-11 | Covidien Lp | Wavelength switching for pulse oximetry |
WO2012047851A1 (en) * | 2010-10-08 | 2012-04-12 | Edwards Lifesciences Corporation | Continuous measurement of total hemoglobin |
US20130030267A1 (en) * | 2011-07-29 | 2013-01-31 | Nellcor Puritan Bennett Llc | Multi-purpose sensor system |
JP2013103094A (en) * | 2011-11-16 | 2013-05-30 | Sony Corp | Measurement device, measurement method, program, and recording medium |
US20130310669A1 (en) * | 2012-05-20 | 2013-11-21 | Jerusalem College Of Technology | Pulmonary pulse oximetry method for the measurement of oxygen saturation in the mixed venous blood |
US11478158B2 (en) * | 2013-05-23 | 2022-10-25 | Medibotics Llc | Wearable ring of optical biometric sensors |
CA2895982A1 (en) | 2012-12-31 | 2014-07-03 | Omni Medsci, Inc. | Short-wave infrared super-continuum lasers for early detection of dental caries |
US10660526B2 (en) | 2012-12-31 | 2020-05-26 | Omni Medsci, Inc. | Near-infrared time-of-flight imaging using laser diodes with Bragg reflectors |
US9164032B2 (en) | 2012-12-31 | 2015-10-20 | Omni Medsci, Inc. | Short-wave infrared super-continuum lasers for detecting counterfeit or illicit drugs and pharmaceutical process control |
WO2014143276A2 (en) | 2012-12-31 | 2014-09-18 | Omni Medsci, Inc. | Short-wave infrared super-continuum lasers for natural gas leak detection, exploration, and other active remote sensing applications |
EP3181048A1 (en) | 2012-12-31 | 2017-06-21 | Omni MedSci, Inc. | Near-infrared lasers for non-invasive monitoring of glucose, ketones, hba1c, and other blood constituents |
US10398364B2 (en) * | 2013-02-13 | 2019-09-03 | Mespere Lifesciences Inc. | Method and device for measuring venous blood oxygenation |
JP6344725B2 (en) * | 2013-05-24 | 2018-06-20 | 国立大学法人浜松医科大学 | Near infrared oxygen concentration sensor for palpation |
US9848808B2 (en) | 2013-07-18 | 2017-12-26 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
JP2015039542A (en) * | 2013-08-22 | 2015-03-02 | セイコーエプソン株式会社 | Pulse wave measurement apparatus |
US9861317B2 (en) * | 2014-02-20 | 2018-01-09 | Covidien Lp | Methods and systems for determining regional blood oxygen saturation |
US10772541B2 (en) * | 2014-08-21 | 2020-09-15 | I. R. Med Ltd. | System and method for noninvasive analysis of subcutaneous tissue |
US10709365B2 (en) | 2014-08-21 | 2020-07-14 | I. R. Med Ltd. | System and method for noninvasive analysis of subcutaneous tissue |
WO2016103323A1 (en) * | 2014-12-22 | 2016-06-30 | 株式会社日立製作所 | Device for optical measurement of living body, analysis device, and analysis method |
AU2016381563B2 (en) | 2015-12-31 | 2022-02-10 | Wear2B Ltd | Device, system and method for non-invasive monitoring of physiological measurements |
KR102464916B1 (en) * | 2016-02-01 | 2022-11-08 | 삼성전자주식회사 | Ring type wearable device |
US20170238819A1 (en) * | 2016-02-18 | 2017-08-24 | Garmin Switzerland Gmbh | System and method to determine blood pressure |
US20190261869A1 (en) * | 2016-11-14 | 2019-08-29 | The General Hospital Corporation | Systems and methods for multi-distance, multi-wavelength diffuse correlation spectroscopy |
US10912469B2 (en) * | 2017-05-04 | 2021-02-09 | Garmin Switzerland Gmbh | Electronic fitness device with optical cardiac monitoring |
US20180317852A1 (en) | 2017-05-04 | 2018-11-08 | Garmin Switzerland Gmbh | Optical motion rejection |
WO2020010276A1 (en) * | 2018-07-05 | 2020-01-09 | Raydiant Oximetry, Inc. | Performing trans-abdominal fetal oxymetry using optical tomography |
US11806119B2 (en) | 2019-03-18 | 2023-11-07 | Garmin Switzerland Gmbh | Electronic device with optical heart rate monitor |
US10918289B1 (en) * | 2019-06-12 | 2021-02-16 | Fitbit, Inc. | Ring for optically measuring biometric data |
CN111466922B (en) * | 2020-05-14 | 2023-11-24 | 中科搏锐(北京)科技有限公司 | Self-adaptive blood oxygen signal acquisition probe, device and method based on near infrared blood oxygen detection |
AU2021350834A1 (en) | 2020-09-24 | 2023-04-27 | Raydiant Oximetry, Inc. | Systems, devices, and methods for developing a fetal oximetry model for use to determine a fetal oximetry value |
US11839490B2 (en) | 2020-11-06 | 2023-12-12 | Garmin International, Inc. | Three wavelength pulse oximetry |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4700708A (en) * | 1982-09-02 | 1987-10-20 | Nellcor Incorporated | Calibrated optical oximeter probe |
US5139025A (en) * | 1983-10-14 | 1992-08-18 | Somanetics Corporation | Method and apparatus for in vivo optical spectroscopic examination |
JPS63218841A (en) * | 1986-10-29 | 1988-09-12 | Nippon Koden Corp | Apparatus for measuring concentration of light absorbing substance in blood |
US4796636A (en) * | 1987-09-10 | 1989-01-10 | Nippon Colin Co., Ltd. | Noninvasive reflectance oximeter |
JPH06103257B2 (en) * | 1988-12-19 | 1994-12-14 | 大塚電子株式会社 | Method and apparatus for measuring absorption coefficient of substance using light scattering |
US5203329A (en) * | 1989-10-05 | 1993-04-20 | Colin Electronics Co., Ltd. | Noninvasive reflectance oximeter sensor providing controlled minimum optical detection depth |
EP0613652B1 (en) * | 1990-02-15 | 1997-04-16 | Hewlett-Packard GmbH | Apparatus and method for non-invasive measurement of oxygen saturation |
US5226417A (en) * | 1991-03-11 | 1993-07-13 | Nellcor, Inc. | Apparatus for the detection of motion transients |
US5218962A (en) * | 1991-04-15 | 1993-06-15 | Nellcor Incorporated | Multiple region pulse oximetry probe and oximeter |
WO1992021283A1 (en) * | 1991-06-06 | 1992-12-10 | Somanetics Corporation | Optical cerebral oximeter |
US5277181A (en) * | 1991-12-12 | 1994-01-11 | Vivascan Corporation | Noninvasive measurement of hematocrit and hemoglobin content by differential optical analysis |
WO1993012712A1 (en) * | 1991-12-31 | 1993-07-08 | Vivascan Corporation | Blood constituent determination based on differential spectral analysis |
EP0555553A3 (en) * | 1992-02-07 | 1993-09-08 | Boc Health Care, Inc. | Improved arterial blood monitoring system |
US5297548A (en) * | 1992-02-07 | 1994-03-29 | Ohmeda Inc. | Arterial blood monitoring probe |
DE4304693C2 (en) * | 1993-02-16 | 2002-02-21 | Gerhard Rall | Sensor device for measuring vital parameters of a fetus during childbirth |
JP2780935B2 (en) * | 1994-09-22 | 1998-07-30 | 浜松ホトニクス株式会社 | Method and apparatus for measuring concentration of absorption component of scattering absorber |
US5524617A (en) * | 1995-03-14 | 1996-06-11 | Nellcor, Incorporated | Isolated layer pulse oximetry |
-
1995
- 1995-03-14 US US08/403,642 patent/US5524617A/en not_active Expired - Lifetime
-
1996
- 1996-03-14 WO PCT/US1996/003536 patent/WO1996028085A1/en active IP Right Grant
- 1996-03-14 EP EP96909705A patent/EP0812148B1/en not_active Expired - Lifetime
- 1996-03-14 CA CA002591551A patent/CA2591551A1/en not_active Abandoned
- 1996-03-14 JP JP52783396A patent/JP3751638B2/en not_active Expired - Fee Related
- 1996-03-14 CA CA002215163A patent/CA2215163C/en not_active Expired - Fee Related
- 1996-03-14 DE DE69632628T patent/DE69632628T2/en not_active Expired - Fee Related
- 1996-06-10 US US08/662,439 patent/US5746206A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5746206A (en) | 1998-05-05 |
DE69632628D1 (en) | 2004-07-08 |
EP0812148B1 (en) | 2004-06-02 |
EP0812148A1 (en) | 1997-12-17 |
CA2215163C (en) | 2007-09-18 |
DE69632628T2 (en) | 2005-06-09 |
JPH11501848A (en) | 1999-02-16 |
WO1996028085A1 (en) | 1996-09-19 |
CA2215163A1 (en) | 1996-09-19 |
JP3751638B2 (en) | 2006-03-01 |
US5524617A (en) | 1996-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5746206A (en) | Isolated layer pulse oximetry | |
US6216021B1 (en) | Method for measuring absolute saturation of time-varying and other hemoglobin compartments | |
EP0613652B1 (en) | Apparatus and method for non-invasive measurement of oxygen saturation | |
EP0619981B1 (en) | Arterial blood monitoring probe | |
US6192261B1 (en) | Photosensor with multiple light sources | |
US6801799B2 (en) | Pulse oximeter and method of operation | |
US5497769A (en) | Photosensor with multiple light sources | |
US6839580B2 (en) | Adaptive calibration for pulse oximetry | |
US5218962A (en) | Multiple region pulse oximetry probe and oximeter | |
EP0689398B1 (en) | Pathlength corrected oximeter | |
US5485838A (en) | Non-invasive blood pressure measurement device | |
JP3950173B2 (en) | Non-intrusive motion adaptive sensor for blood analysis | |
JP3789487B2 (en) | False signal detection method in pulse oximetry | |
EP1729633B1 (en) | Pulse oximetry motion artifact rejection using near infrared absorption by water | |
EP0760476A2 (en) | Method of quantitatively determining one or more characteristics of a substance | |
EP0555553A2 (en) | Improved arterial blood monitoring system | |
RU2040912C1 (en) | Optical method and device for determining blood oxygenation | |
WO2010004554A1 (en) | Method and system for non-invasively monitoring fluid flow in a subject | |
JP3035791B2 (en) | Method and apparatus for measuring light-absorbing substance concentration in living tissue and thickness of intervening tissue in living body | |
US5908384A (en) | Apparatus for non-invasive measurement within a human or animal body | |
CA1157529A (en) | Method and apparatus for monitoring metabolism in body organs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |